The Omega-Project - A comparison of two diagnostic strategies for risk- and cost-oriented management of dyspepsia

European Journal of Gastroenterology and Hepatology

Volumn 9, Issue 4, 1997, Pages 337-343

  Brignoli, Reto ^a,c   Watkins, Patrick ^a   Halter, Fred ^b  

^a Janssen Research Foundation   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c Cilag AG   (Switzerland)

Author keywords

Carcinoma prevalence; Cisapride; Domperidone; Dyspepsia management; Mandatory endoscopy; Peptic lesions; Prokinetic drugs; Secondary costs; Selective endoscopy; Therapeutic outcome

Indexed keywords

CISAPRIDE; DOMPERIDONE; PROKINETIC AGENT;

ARTICLE; CANCER INCIDENCE; CLINICAL TRIAL; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC PROCEDURE; DYSPEPSIA; GASTROINTESTINAL ENDOSCOPY; HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; STOMACH CANCER; TREATMENT OUTCOME;

EID: 0030935753     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-199704000-00005     Document Type: Article

References (15)

1. Lindell GH, Celebioglu F, Graffner HO: Non-ulcer dyspepsia in the long-term perspective. Eur J Gastroenterol Hepatol 1995, 7:829-833.
2. Schläpfer ThE, Fried M, Koerfer J, et al.: Selbstbehandlung der Dyspepsie. Eine epidemiologische Untersuchung bei der Schweizer Bevölkerung. Der informierte Arzt - Gazette Médicale 1993, 14:1295-1301.
3. Talley NJ, McNeil D, Piper DW: Discriminant value of dyspeptic symptoms: a study of the clinical presentation of 221 patients with dyspepsia of unknown cause, peptic ulceration, and cholelithiasis. Gut 1987, 28:40-46.
4. Halter F, Miazza B, Brignoli R: Cisapride or cimetidine in the treatment of functional dyspepsia. Results of a double-blind, randomized, Swiss multicentre study. Scand J Gastroenterol 1994, 29:618-623.
5. Carvalhinhos A, Fidalgo P, Freire A, et al.: Cisapride compared with ranitidine in the treatment of functional dyspepsia. Eur J Gastroenterol Hepatol 1995, 7:411-417.
6. Silverstein MD, Petterson T, Talley NJ: Initial endoscopy or empirical therapy with or without testing for Helicobacter pylori for dyspepsia: a decision analysis. Gastroenterology 1996, 110:72-83.
7. Bytzer P, Hansen JM, Schaffalitzky de Muckadell OB: Empirical H2-blocker therapy or prompt endoscopy in management of dyspepsia. Lancet 1994, 343:811-816.
8. Bytzer P, Hansen JM, Schaffalitzky de Muckadell OB: Survey of patients with upper gastrointestinal tract dyspepsia. A trial of H2 blocker therapy or endoscopy - a randomised trial of 2 management methods. Ugeskr Laeger 1995, 157:893-897.
9. Halter F, Dyspepsia and H pylori: to endoscope or not to endoscope? Letter to the editor. Gastroenterology 1996, 111:1159.
10. Brignoli R, Merki H, Miazza B, et al.: Endoscopic findings in volunteers and dyspeptic patients. [Endoskopische Befunde bei freiwilligen und dyspeptischen Patienten.] Schweiz Med Wochenschr 1994, 124:1240-1247.
11. Sonnenberg A, Townsend WF, Müller AD: Evaluation of dyspepsia and functional gastrointestinal disorders: a cost-benefit analysis of different approaches. Eur J Gastroenterol Hepatol 1995, 7:655-659.
12. Koch M, Capurso LB: A patient with dyspepsia: a model for decision analysis. In Data Analysis for Clinical Medicine. Edited by Chalmers G. Rome: International University Press; 1988:183-203.
13. Heikkinen M, Pikkarainen P, Takala J, et al.: Etiology of dyspepsia: 400 unselected consecutive patients in general practice. Scand J Gastroenterol 1995, 30:519-523.
14. Knill Jones RP: A formal approach to symptoms in dyspepsia. Clin Gastroenterol 1985, 14:517-529.
15. Fox-Rushby J: In Quality of Life Assessment. Edited by Orley J, Kuyken W. Berlin, Heidelberg, New York: Springer-Verlag; 1994:61-74.